Insight - Innovation - Access - Engagement - Partnering
The global partnering and investment summit for global leaders and innovators in CNS neuroscience and psychiatric drug discovery, development, platforms and technologies.
Convened by-invitation, Bio-Neuroscience is a high level, boutique gathering of key thought leaders, innovators and decision-makers from all key stakeholder groups crucial to the discovery, development and market launch of novel therapeutics and breakthrough platforms and technologies.
High level access, serious, sustained engagement, discussion and networking with key stakeholders. Sharing models, lessons learned, solutions, ways forward and best practices. A truly curated and unique summit to facilitate business and accelerate innovation.
We are honored by the support of our Advisory Board.
Meet them in person at the summit.
Executive Director, F-Prime Biomedical Research Initiative
Venture Partner - SV Health Investors, CEO - LoQus23 Therapeutics
Managing Director - Dolby Family Ventures
Global Head Translational Medicine CNS & Emerging Areas - Boehringer Ingelheim
Kalpana Merchant, PhD
Adjunct Professor of Neurology, Northwestern University Feinberg School of Medicine Founder President & CSO, TransThera Consulting Co.
Juan Carlos Lopez
Managing Director, Research Grants - RTW Charitable Foundation. Formerly Chief Editor - Nature Medicine & Founding Editor - Nature Reviews Neuroscience
Commercial Scientist, Entrepreneur & Investor. Chairperson - Monument Therapeutics, Talisman Therapeutics, Ubiqent, NuVision Biotherapies
Pieter van Bokhoven
Chief Scientific Officer - Amsterdam Neuroscience IAO - VUMC
Andrea Soto Padilla, M.D. PhD
Business Development - Amsterdam UMC
Founder - NeuroCentury; Practice Lead Neurotechnology, ICFG; Senior Advisor on Brain Health, FIPRA.
Managing Director, Head of Healthcare & Life Sciences - M-Ventures
Christian J. Suojanen
Founder & CEO - Broadreach Global, Member of the Board - European Brain Foundation
Confirmed speakers include:
Head of the Dementia Fund, Partner - EQT Life Sciences, Professor of Neurology - Amsterdam University Medical Center
President - European College of NeuroPsychopharmacology (ECNP), Professor of Behavioral Neuroscience - Groningen Institute for Evolutionary Life Sciences, University of Groningen
Director Of Business Development & Innovation - Otsuka Pharmaceutical Companies Europe
José Luis Lanciego
Chair - International Brain Research Organization Pan-European Committee, Head, Laboratory of Functional Neuroanatomy of the Basal Ganglia, CNS Gene Therapy Program - CIMA, University of Navarra
Partner - Ysios Capital
Executive Director - European Brain Council
CEO – AccelBio, Executive Chairman – Evergreen Biosciences, Advisory Board Member – Alzheimers Drug Discovery Foundation, New York
Managing Partner - Kurma Partners
Co-founder & General Partner - Panakes Partners
Managing Director - EQT Life Sciences
Global Head of CNS BD&L - Boehringer Ingelheim
Founder & Chairman of the Board - Oryzon
Two days of sustained, interactive discussion, networking and partnering with:
Senior industry leaders from pharma, large biotech and healthcare companies. Heads of therapeutic area, R&D, clinical development, biological sciences, M&A, scouting, business development & licensing.
Key Opinion Leaders
Key Opinion Leaders from all stakeholder groups crucial to the successful development, approval and market launch of novel CNS neuroscience and psychiatric therapeutics, platforms and technologies.
Founders & CEOs
From startup and growth companies at the cutting edge of the future of CNS neuroscience and psychiatric drug discovery, development, advanced therapies, platforms and technologies.
Government & NGOs
Public agencies, funding bodies, foundations, societies, associations, patient organizations & NGOs in CNS neurosciences and psychiatry.
In CNS neuroscience and psychiatric drug development, platforms and technologies.
VC and corporate venture, private equity, family offices, angels & HNW.
A selected group of leading specialized advisors and consultants with deep subject matter expertise relevant to participants.
A curated selection of the best, world-class , innovative CNS neurosciences and psychiatric drug development companies with potential to transform healthcare, patient outcomes or markets. Selection is by excellence and potential, not by price tag.
There is no cost to present beyond the regular startup or private company registration fees.
Presenting Companies Receive:
- A 3 minute pitch plus 3 minutes of Q&A with an expert panel of relevant investors and industry: In the plenary session.
- Exclusive post presentation meeting space:
- Meeting Space: one of five reserved meeting spaces prominently placed next to the main networking area.
- 30 minutes in the networking break immediately following the presentation session.
- 2 Days of sustained engagement with the best network of innovators, investors, industry leaders & decision-makers in CNS neuroscience and psychiatric drug development and biopharma.
- Full access to the summit programme.
- Option to add an exclusive company exhibition stand.
Amstelpark 1, Europaboulevard,
1083 HZ Amsterdam, Netherlands
Rosarium Amstelpark is one of the most presitigious meeting venues in Amsterdam, providing exceptional space for for plenary sessions, meetings and networking. With an open lobby area, wine bar, and adjacent Floriade gardens, it is a unique venue for a high level, by invitation summit like Bio-Neuroscience. Easily accessible by car (parking available), train, or boat.
GET IN TOUCH
Reach us here if you like to
Nominate a speaker
Apply to present your company or technology
Enquire about sponsorship & exhibition opportunities
Be the first to know
Subscribe and be among the first to receive all Broadreach Global updates, announcements and invitations.
Please make sure to double check your email address.